Cerus’ Notified Body, TÜV-SÜD, has completed the review of the clinical module for the CE Mark submission for INTERCEPT Red Blood Cells (RBCs) CONCORD, Calif. / Jul 02, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today a European regulatory update on the INTERCEPT RBC program. “We are pleased to report that the European regulatory review for INTERCEPT RBC is advancing ahead of plan and that TÜV-SÜD, our... Read More

CONCORD, Calif. / Jun 13, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. This year’s theme, “Give blood, give hope: together we save lives” is a reminder... Read More

CONCORD, Calif. / Jun 03, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46 th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus’ Investor Relations website... Read More

Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells CONCORD, Calif. / May 29, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced it will showcase the latest INTERCEPT Blood System clinical data at the 35 th Regional International Society of Blood Transfusion (ISBT) Congress being held May 31 to... Read More

France and Switzerland approve INT200 for use with the INTERCEPT Blood System for Platelets and Plasma CONCORD, Calif. / May 28, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product Safety (ANSM) and the other by the Swiss Agency for Therapeutic Products (Swissmedic). The INT200, the Company’s... Read More

First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million First Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million Conference Call Today at 4:30 pm ET CONCORD, Calif. / May 01, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today financial results for the first... Read More

CONCORD, Calif. / Apr 17, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and... Read More

Regulatory Approval Allows Company to Initiate Commercialization of the Illumination Device throughout the European Union CONCORD, Calif. / Mar 05, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today the CE mark approval of its next-generation LED-based illumination device, or the INT200, for the INTERCEPT Blood System for platelets and plasma under the European Union (EU) Medical Device Regulation (MDR).... Read More

Full-Year and Fourth Quarter 2024 Product Revenues Increased 15% and 9%, respectively, from Prior Year Periods Fourth straight quarter of positive operating cash flows Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 – $200 million CONCORD, Calif. / Feb 20, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024.... Read More

CONCORD, Calif. / Feb 19, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that members of Cerus’ management are scheduled to present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 11:10 a.m. EST. A live webcast of the fireside chat will be available via the following link . A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated... Read More

CONCORD, Calif. / Feb 07, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2024 financial results will be released on Thursday, February 20, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business... Read More

Preliminary Full-Year 2024 Product Revenues Total $180.3 million, 15% Over 2023 Results and Exceed Prior Product Revenue Guidance 2025 Product Revenues Expected to be Between $194-$200 million, Reflecting 8%-11% Growth Year-Over-Year CONCORD, Calif. / Jan 13, 2025 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2024 and provided product... Read More

CONCORD, Calif. / Nov 13, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to participate in the Stifel 2024 Healthcare Conference on Monday, November 18 th at 4:10 PM ET, and will attend the Craig-Hallum Alpha Select Conference on Tuesday, November 19 th . A live webcast of the Stifel 2024 Healthcare Conference will be available... Read More

Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million CONCORD, Calif. / Oct 30, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced financial results for its third... Read More

CONCORD, Calif. / Oct 18, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2024 financial results will be released on Wednesday, October 30, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and... Read More

Presentations Highlight the Unique Benefits of Real-world Utilization of INTERCEPT-treated Blood Products, Including INTERCEPT Fibrinogen Complex, and Recent Findings from the Phase 3 ReCePI Clinical Trial CONCORD, Calif. / Oct 18, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced a selection of abstracts to be presented at the 2024 Association for the Advancement of Blood & Biotherapies (AABB) Annual... Read More

Company to Host Conference Call and Webcast on Wednesday, October 16, 2024 at 5:00 p.m. EDT CONCORD, Calif. / Oct 16, 2024 / Business Wire / Cerus Corporation (Nasdaq:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe: U.S. – New $248 million BARDA contract supports program beyond U.S. Phase 3 studies through anticipated PMA licensure and into commercialization Europe – CE... Read More

First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2024 Product Revenue Guidance Range from $172-175 Million to $175-178 Million CONCORD, Calif. / Aug 01, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced financial results for its second quarter and six months ended June 30, 2024. Total revenue for the three and six months ended June 30, 2024 was comprised of (... Read More

CONCORD, Calif. / Jul 18, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and... Read More

CONCORD, Calif. / Jul 02, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, Mr. Gregory served as President, Global... Read More

Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs CONCORD, Calif. / Jun 21, 2024 / Business Wire / Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th International Congress of the International Society of Blood Transfusion (ISBT), taking place... Read More

CONCORD, Calif. / Jun 14, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2024. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. For 2024, the focus of this day is on all blood donors, essential for ensuring... Read More

CONCORD, Calif. / May 22, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 21 st Annual Craig-Hallum Institution Investor Conference in Minneapolis, on Wednesday, May 29 th . ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood... Read More

First Quarter Product Revenue Increased 24% from Prior Year Quarter CONCORD, Calif. / May 02, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2024. Recent highlights include: First-quarter 2024 total revenue was comprised of ( in thousands, except %) : Three Months Ended March 31, Change 2024 2023 $ % Product Revenue $ 38,365 $ 30,974 $ 7,391 24%... Read More

CONCORD, Calif. / Apr 18, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and... Read More

CONCORD, Calif. / Mar 26, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. This approval extends the set shelf life by six months from the existing six-month shelf life that took effect following a set component change... Read More

Trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury for INTERCEPT Red Blood Cells compared to conventional red blood cells CONCORD, Calif. / Mar 19, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to... Read More

Sequential Revenue Growth in the Fourth Quarter Driven by Sales in North America Narrowed GAAP Net Loss Attributable to Cerus Corporation to $1.3 Million for the Fourth Quarter and Achieved Goal of Adjusted EBITDA Breakeven for the Fourth Quarter Reiterating Full-Year 2024 Product Revenue Guidance Range of $172-175 Million CONCORD, Calif. / Mar 05, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced... Read More

CONCORD, Calif. / Feb 20, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business... Read More

CONCORD, Calif. / Feb 01, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced management participation in two upcoming investor conferences. Management plans to attend the BTIG 11 th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13 th and will participate in TD Cowen’s 44 th Annual Health Care Conference on Wednesday, March 6 th at 11:10 AM EST. A live webcast... Read More

Preliminary Fourth Quarter and Full-Year 2023 Product Revenues of $46.8 million and $156.4 million, respectively 2024 Product Revenues expected to be between $172-$175 million, reflecting 10%-12% growth year over year CONCORD, Calif. / Jan 08, 2024 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2023 and provided product revenue guidance for... Read More

CONCORD, Calif. / Nov 03, 2023 / Business Wire / Cerus Corporation (NASDAQ:CERS) announced today that the Company will participate in two upcoming investor conferences: William “Obi” Greenman, Cerus’ president and chief executive officer, is scheduled to participate in a fireside chat at The Stifel 2023 Healthcare Conference on Tuesday, November 14 th , at 4:10 p.m. EST, at the Lotte New York Palace Hotel. A live webcast of... Read More

CONCORD, Calif. / Nov 02, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: Third quarter 2023 total revenue of $47.3 million was comprised of total product revenue of $39.8 million and government contract revenue of $7.5 million. Completed Phase 3 ReCePI study enrollment in cardiovascular surgery patients, with... Read More

CONCORD, Calif. / Oct 19, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and... Read More

Workshop and Presentations Highlight the Benefits of Real-world Utilization of INTERCEPT-treated Blood Products, including the INTERCEPT Blood System for Platelets and INTERCEPT Fibrinogen Complex CONCORD, Calif. / Oct 10, 2023 / Business Wire / Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14... Read More

CONCORD, Calif. / Sep 27, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that Alicia Goodman has been appointed to the role of Chief Human Resources Officer (CHRO). In this role, she will focus on sustaining and evolving the talent and organizational structure to support the future of the business as the leader in safeguarding the global blood supply. Ms. Goodman will also serve as a member of the... Read More

CONCORD, Calif. / Sep 12, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that Kevin Green, Cerus’ chief financial officer, is scheduled to participate at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, at 10:30 a.m. EST. A live webcast of the fireside chat will be available at https://wsw.com/webcast/cantor19/cers/2090781 . A replay will be available for 90 days after the... Read More

CONCORD, Calif. / Aug 02, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2023. Recent highlights include: Second quarter 2023 total revenue of $47.7 million was comprised of total product revenue of $38.9 million and government contract revenue of $8.9 million. Received positive feedback for INTERCEPT Red Blood Cells CE Mark submission in... Read More

CONCORD, Calif. / Jul 19, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and... Read More

Symposium and Abstracts Highlight Data from Studies of INTERCEPT Platelets and Plasma as well as Developmental Programs CONCORD, Calif. / Jun 15, 2023 / Business Wire / Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and a lunch symposium at the 33 rd Regional International Society of Blood Transfusion (ISBT) Congress, taking place in Gothenburg, Sweden, from June 17 through June 21. Transfusion... Read More

CONCORD, Calif. / Jun 14, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2023. In 2005, the World Health Assembly designated June 14 as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. For 2023, the focus of this day is on those patients who rely on blood products over... Read More

Additional $8.7 million funding to support advancement towards FDA registration and full-scale product commercialization CONCORD, Calif. / Jun 05, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded an additional $8.7 million contract amendment to the original $9.1 million contract by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for... Read More

Reiterating Full-Year 2023 Product Revenue Guidance Range of $165-170 Million CONCORD, Calif. / May 04, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) today announced financial results for the first quarter ended March 31, 2023. Recent highlights include: First quarter 2023 total revenue of $38.5 million was comprised of ( in thousands, except %) : Three Months Ended March 31, Change 2023 2022 $ % Product Revenue $... Read More

CONCORD, Calif. / Apr 20, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and... Read More

CONCORD, Calif. / Feb 15, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business... Read More

CONCORD, Calif. / Feb 10, 2023 / Business Wire / Cerus Corporation (Nasdaq: CERS) announced today that the Company will participate in two upcoming investor conferences. William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to be in attendance at BTIG’s MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 14 th and Wednesday, February 15 th . William ‘Obi’... Read More

Preliminary Fourth Quarter and Full-Year 2022 Product Revenues of $44.0 million and $162.0 million reflecting year-over-year growth of 10% and 24%, respectively Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2022 and provided product revenue guidance for full-year 2023. Cerus’ unaudited preliminary product revenue for the fourth quarter of 2022 totaled $44.0... Read More